Fesoterodine Uses, Dosage, Side Effects & Warnings | DrugsAtlas
Authoritative Clinical Reference
Navigation
DRUG NAME: Fesoterodine
Therapeutic Class: Anticholinergic (Antimuscarinic Agent)
Subclass: Urinary Antispasmodic
Speciality: Urology
Schedule (India): Schedule H
Route(s): Oral
Formulations Available in India:
- Fesoterodine fumarate 4 mg extended-release tablets
- Fesoterodine fumarate 8 mg extended-release tablets
INDICATIONS + DOSING — FOR CLINICIAN USE ONLY
Primary Indications (Approved / Standard in India):
Overactive Bladder (OAB) with Urge Urinary Incontinence, Urgency, and Frequency
| Parameter | Recommendation |
|
Starting dose
|
4 mg once daily |
|
Titration
|
May increase to 8 mg once daily after 2–4 weeks based on response and tolerability |
|
Usual maintenance dose
|
4–8 mg once daily |
|
Maximum dose
|
8 mg once daily |
Clinical Notes:
- Swallow tablets whole; do not crush, chew, or divide
- May be taken with or without food
- Therapeutic response typically observed within 2–4 weeks
- Dose adjustment required in renal/hepatic impairment and concurrent CYP3A4 inhibitor use
- Not effective for stress urinary incontinence
- If no improvement after 8–12 weeks at maximum tolerated dose, reconsider diagnosis or alternative therapy
Secondary Indications — Adults (Off-label):
| Indication | Dose | Duration | Notes |
| Neurogenic detrusor overactivity | 4 mg once daily; may increase to 8 mg if tolerated | Long-term; individualised |
OFF-LABEL; Specialist only (Urology/Neurology); Used in patients unresponsive to oxybutynin/tolterodine; Based on limited RCTs and Indian tertiary care urology practice
|
PAEDIATRIC DOSING (Specialist Only)
Primary Indications:
Not approved for use in children and adolescents (<18 years) in India.
No established paediatric dosing for approved indications.
Secondary Indications — Paediatrics (Off-label):
| Indication | Age/Weight | Dose | Notes |
| Severe neurogenic bladder (spina bifida, spinal cord pathology) | ≥12 years (under exceptional circumstances) | 4 mg once daily (do not exceed adult maximum) |
OFF-LABEL; Specialist only (Paediatric Urologist); Very limited safety data; Oxybutynin preferred as first-line; Based on extrapolated pharmacokinetics and limited European paediatric use data
|
Minimum Age: Not recommended below 18 years except under specialist supervision for refractory neurogenic bladder
Safety Monitoring:
- ECG before initiation and periodically
- Post-void residual urine measurement
- Renal function monitoring
- Cognitive and behavioural assessment
- Monitor for anticholinergic side effects
RENAL ADJUSTMENT
| Renal Function | Recommendation |
| eGFR ≥30 mL/min/1.73m² | No dose adjustment required |
| eGFR <30 mL/min/1.73m² | Maximum dose 4 mg once daily |
| End-stage renal disease / Dialysis | Maximum dose 4 mg once daily; use with caution; limited data |
Note: Active metabolite (5-HMT) clearance is reduced in renal impairment; monitor for enhanced anticholinergic effects.
HEPATIC ADJUSTMENT
| Severity | Recommendation |
|
Mild impairment (Child-Pugh A)
|
No dose adjustment required; initiate at 4 mg once daily |
|
Moderate impairment (Child-Pugh B)
|
Maximum dose 4 mg once daily; use with caution |
|
Severe impairment (Child-Pugh C)
|
Contraindicated; avoid use |
CONTRAINDICATIONS
- Known hypersensitivity to fesoterodine, tolterodine, or any formulation excipient
- Urinary retention
- Gastric retention or severe gastrointestinal motility disorders
- Uncontrolled narrow-angle (angle-closure) glaucoma
- Myasthenia gravis
- Severe hepatic impairment (Child-Pugh C)
- Concomitant use with potent CYP3A4 inhibitors in patients with severe renal impairment
CAUTIONS
- Controlled narrow-angle glaucoma (with ophthalmologist clearance; monitor IOP)
- Bladder outflow obstruction (including prostatic hypertrophy): Risk of urinary retention
- Gastrointestinal obstructive disorders
- Gastro-oesophageal reflux disease (GERD)
- Constipation or reduced GI motility
- Elderly patients (increased anticholinergic sensitivity)
- History of QT prolongation or concurrent use of QT-prolonging drugs
- Cardiac arrhythmias or cardiovascular disease
- Cognitive impairment or dementia
- Autonomic neuropathy
- Hot environment exposure (decreased sweating)
- Concurrent use with other anticholinergic medications
- Moderate renal or hepatic impairment
PREGNANCY
| Aspect | Recommendation |
|
Risk category
|
Limited human data; animal studies show risk at high doses; potential risk to fetus |
|
Preferred alternatives
|
Non-pharmacological measures (bladder training, pelvic floor exercises) first-line; if drug required, oxybutynin has more pregnancy experience |
|
When to use
|
Only if clearly indicated and benefit outweighs potential risk; avoid in first trimester; specialist input essential |
|
What to monitor
|
Maternal: Anticholinergic side effects, urinary retention; Fetal: Growth monitoring if prolonged use |
LACTATION
| Aspect | Recommendation |
|
Compatibility
|
Unknown; limited data on excretion in human milk |
|
Preferred alternatives
|
Non-pharmacological measures; oxybutynin if drug required (more established data) |
|
Expected drug level in milk
|
Low (expected based on pharmacokinetic properties) |
|
What to monitor in infant
|
Dry mouth, poor suckling, constipation, irritability, sedation, decreased urine output |
ELDERLY
| Aspect | Recommendation |
|
Recommended starting dose
|
4 mg once daily |
|
Titration
|
Slow; assess response and tolerability for 4 weeks before considering dose increase |
|
Extra risks
|
Cognitive impairment, confusion, hallucinations, constipation, urinary retention, falls, dry mouth, blurred vision, heat intolerance |
|
Special precautions
|
Avoid 8 mg dose in patients with cognitive impairment or high anticholinergic burden; periodic cognitive assessment; review total anticholinergic load from all medications; consider mirabegron as alternative in cognitively at-risk patients |
MAJOR DRUG INTERACTIONS
| Interacting Drug/Class | Mechanism | Clinical Effect | Recommendation |
|
Potent CYP3A4 inhibitors (ketoconazole, itraconazole, clarithromycin, ritonavir, nelfinavir)
|
Inhibit metabolism of active metabolite | Significantly increased fesoterodine exposure | Maximum dose 4 mg/day; contraindicated in severe renal impairment |
|
QT-prolonging drugs (amiodarone, sotalol, haloperidol, domperidone, ondansetron)
|
Additive QT prolongation | Increased risk of torsades de pointes | Avoid combination; if unavoidable, baseline ECG and monitor |
|
Other anticholinergics (TCAs, antihistamines, antipsychotics)
|
Additive pharmacodynamic effect | Central and peripheral anticholinergic toxicity | Avoid combination; if unavoidable, monitor cognition and reduce doses |
|
Potassium chloride (slow-release oral)
|
Reduced GI motility | GI mucosal ulceration | Avoid combination |
MODERATE DRUG INTERACTIONS
| Interacting Drug/Class | Clinical Effect | Recommendation |
|
Moderate CYP3A4 inhibitors (erythromycin, fluconazole, verapamil, diltiazem)
|
Increased fesoterodine levels | Monitor for enhanced side effects; consider limiting dose to 4 mg |
|
CYP3A4 inducers (rifampicin, carbamazepine, phenytoin, phenobarbital)
|
Reduced fesoterodine efficacy | Monitor response; may need alternative agent |
|
CNS depressants (benzodiazepines, opioids, alcohol)
|
Additive sedation | Use with caution; counsel against alcohol |
|
Cholinesterase inhibitors (donepezil, rivastigmine)
|
Pharmacodynamic antagonism | Reduced efficacy of both; avoid if possible in dementia |
|
Warfarin
|
No significant pharmacokinetic interaction | Monitor INR during initiation as precaution |
COMMON ADVERSE EFFECTS
- Dry mouth (most common; ~20–30%)
- Constipation
- Dry eyes
- Headache
- Dyspepsia
- Nausea
- Abdominal pain
- Urinary tract infection
- Dizziness
- Insomnia
- Fatigue
SERIOUS ADVERSE EFFECTS
| Adverse Effect | Clinical Significance |
|
Acute urinary retention
|
Especially in men or patients with bladder outflow obstruction; discontinue and catheterise if required |
|
QT prolongation / Arrhythmia
|
Dose-dependent; obtain baseline ECG in high-risk patients |
|
Angioedema
|
Rare; discontinue immediately and manage airway |
|
Cognitive impairment / Delirium
|
Especially in elderly; requires discontinuation |
|
Hallucinations
|
More common in elderly or those with CNS disease; discontinue |
|
Severe allergic reactions
|
Urticaria, anaphylaxis; discontinue and treat |
|
Heat stroke
|
Due to decreased sweating; counsel patients |
MONITORING REQUIREMENTS
| Phase | Parameters |
|
Baseline
|
Post-void residual (PVR) urine volume; uroflowmetry if outflow obstruction suspected; renal function (eGFR); hepatic function (LFTs); ECG in high-risk cardiac patients; cognitive assessment in elderly |
|
After initiation / dose change
|
Assess symptom improvement at 2–4 weeks; evaluate for adverse effects (dry mouth, constipation, urinary retention); recheck PVR if symptoms suggest retention |
|
Long-term
|
Periodic cognitive assessment in elderly (every 6–12 months); bowel function; renal function annually; intraocular pressure if glaucoma risk; reassess need for continued therapy annually |
BRANDS AVAILABLE IN INDIA
| Brand Name | Manufacturer | Formulation |
| Toviaz | Pfizer | ER 4 mg, 8 mg tablets |
| Festero | Sun Pharma | ER 4 mg, 8 mg tablets |
| Fesoter | Intas | ER 4 mg, 8 mg tablets |
Note: Availability may vary; verify stock before prescribing
PRICE RANGE (INR)
| Formulation | Price Range | Notes |
| ER 4 mg tablet | ₹25–₹45 per tablet | — |
| ER 8 mg tablet | ₹35–₹55 per tablet | — |
|
NLEM status
|
Not included in NLEM 2022 | Not under NPPA price control |
|
Availability
|
Private pharmacies only | Limited government supply |
CLINICAL PEARLS
- Better CNS tolerability: Fesoterodine may have lower CNS penetration compared to oxybutynin; consider in patients experiencing cognitive side effects with oxybutynin
- Prodrug advantage: Fesoterodine is a prodrug converted to 5-hydroxymethyl tolterodine (same active metabolite as tolterodine) by ubiquitous esterases; less interindividual variability compared to tolterodine
- Dry mouth management: Most common dose-limiting side effect; suggest sugar-free lozenges, frequent sips of water; if intolerable, reduce dose or switch to mirabegron
- Exclude obstruction first: Always assess for bladder outlet obstruction before initiating; check post-void residual volume
- Elderly caution: Limit to 4 mg in patients with cognitive concerns or high anticholinergic burden; regular cognitive monitoring essential
- Duration of trial: Allow 4–8 weeks for full therapeutic effect; if no benefit at maximum dose after 8–12 weeks, reconsider diagnosis or switch to alternative (mirabegron, combination therapy, or specialist referral)
TAGS
fesoterodine; overactive-bladder; urinary-incontinence; antimuscarinic; urinary-antispasmodic; OAB; elderly-caution; CYP3A4-substrate; renal-adjustment; urology
VERSION
RxIndia v1.0 — 03 Feb 2026
REFERENCES
- CDSCO approved prescribing information
- Indian Pharmacopoeia / National Formulary of India
- API Textbook of Medicine
- AIIMS Urology Department protocols
- Goodman & Gilman’s The Pharmacological Basis of Therapeutics
- Harrison’s Principles of Internal Medicine
- International RCTs (for off-label evidence basis; marked as OFF-LABEL)
⚖️
Clinical Responsibility
This platform is designed strictly for healthcare professionals. Data provided is synthesized from authoritative pharmacological sources and clinical registries. Do not use for consumer medical decisions. Always verify critical dosing and contraindications with official institutional protocols and peer-reviewed journals.
Content Feedback
Is this information helpful?
Help us improve our clinical database for the medical community.